Galectin Therapeutics Inc.
NASDAQ:GALTBiotechnology
+$0.05 today
- Market cap
- $196.25M
- Beta
- 0.49
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.40
Volume 0.23M
Average 0.32M
GALT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Galectin Therapeutics Inc.NASDAQ: GALT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $2.23M fell 65.6% year over year, ahead of the -71.3% change in trailing-twelve-month research & development. Sequentially, it rose 15.4% from the prior quarter. Over 3 fiscal years it compounded at -23.4% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -65.6% holds above the trailing-twelve-month pace of -71.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 14.29M USD
- Year-over-year change
- -60.9%
- 4-year CAGR
- -12.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.29M | -60.9% |
| FY2024 | 2024-12-31 | 36.57M | +13.8% |
| FY2023 | 2023-12-31 | 32.13M | +1.2% |
| FY2022 | 2022-12-31 | 31.74M | +33.2% |
| FY2021 | 2021-12-31 | 23.82M | — |
Research & Development vs competitors
How GALT compares with its peers on the latest reported figures
- GALT's LTM Mar 2026 research & development of $10.04M is the lowest of the 10 companies compared; the peer median is $58.13M.
- Its year-over-year change of -71.3% is the lowest of 9, against a peer median of +18.0%.
- Over three fiscal years its annual growth of -23.4% compares with a peer median of +13.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $137.53M | -14.3% | -5.0% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $98.75M | +56.7% | +82.8% | — |
| LTM Mar 2026 | $94.92M | +19.3% | +28.8% | — | |
| LTM Mar 2026 | $66.77M | -12.8% | -2.0% | 185483.3% | |
| LTM Mar 2026 | $58.13M | +16.8% | +6.7% | — | |
| LTM Mar 2026 | $54.53M | -11.0% | -9.3% | 2944.3% | |
| LTM Mar 2026 | $35.87M | +29.3% | +13.9% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $28.47M | — | +131.7% | — |
| LTM Mar 2026 | $26.95M | +28.1% | +46.4% | — | |
| LTM Mar 2026 | $10.04M | -71.3% | -23.4% | — | |
| Peer median (excluding GALT) | $58.13M | +18.0% | +13.9% | 94213.8% | |
Competitors are the stored peer set for GALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.82M | 31.74M | 32.13M | 36.57M | 14.29M |
| Selling, General & Admin | 6.36M | 6.62M | 5.94M | 5.86M | 5.8M |
| Operating Expenses | 30.18M | 38.35M | 38.07M | 42.43M | 20.09M |
| Depreciation & Amortization | 41K | 32K | 33K | 37K | 53K |
| EBITDA | (30M) | (37.71M) | (38.24M) | (41.47M) | (23.45M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (30.18M) | (38.35M) | (38.07M) | (42.43M) | (20.09M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3K | 52K | 230K | 338K | 126K |
| Interest Expense | 489K | 1.03M | 2.79M | 5.54M | 7.33M |
| Other Income / Expenses | (348K) | (424K) | (2.99M) | (4.61M) | (10.75M) |
| Income Before Tax | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| EPS (Diluted) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) |
| Weighted Avg Shares | 58.53M | 59.39M | 60.16M | 62.31M | 63.9M |
| Weighted Avg Shares (Diluted) | 58.53M | 59.39M | 60.16M | 62.31M | 63.9M |
Galectin Therapeutics Inc.
NASDAQ:GALT
Intrinsic Alpha fair value
Locked
Current Price
$2.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.